Re-Aim Therapeutics
PrivateLast Round
Seed
May 18, 2026
Total Funding Raised
$9.4M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Re-Aim Therapeutics is a biotechnology company that develops targeted biologics to treat autoimmune diseases by selectively depleting pathogenic T cell subsets.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Re-Aim Therapeutics Comparables
Compare Re-Aim Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hillstar Bio | 85% | |
| Elemental Biologics | 85% | |
| Abcuro | 76% | |
Re-Aim Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 18, 2026 |
Re-Aim Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Syncona | Seed |
| Oxford Science Enterprises | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 18, 2026
$9.4M round led by Oxford Science Enterprises and Syncona.
Re-Aim Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Re-Aim Therapeutics's valuation, stock price, and market status.